About Enhancer
| Enhancer ID: |
E_02_0236 |
| Species: |
human |
| Position :
|
chr2:136111778-136113778
  |
| Biosample name: |
|
| Experiment class :
|
High+Lowthroughput |
| Enhancer type: |
Enhancer |
| Disease: |
Miocardial infarction |
| Pubmed ID: |
30696265
|
| Enhancer experiment: |
FISH |
| Enhancer experiment description: |
These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo. |
About Target gene
| Target gene : |
CXCR4 |
| Strong evidence: |
qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: |
RNA-Seq |
| Target gene experiment description: |
These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo. |
About TF
| TF name : |
-- |
| TF experiment: |
FISH |
| TF experiment description: |
These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo. |
About Function
| Enhancer function : |
These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo. |
| Enhancer function experiment: |
Immunohistochemical staining |
Enhancer function
experiment description: |
These data confirm CXCR4 blockade as a promising treatment strategy after MI. We identify dendritic cell-primed splenic Treg cells as the central arbiters of these therapeutic effects and thereby delineate a pharmacological strategy to promote infarct repair by augmenting Treg cell function in vivo. |
About SNP
Upstream Pathway Annotation of TF
| GeneName |
Pathway Name |
Source |
Gene Number |
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene
Expression of target genes for the
enhancer
Enhancer associated SNPs